Clinical Trials
5
Active:2
Completed:1
Trial Phases
2 Phases
Phase 1:3
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (5 trials with phase data)• Click on a phase to view related trials
Phase 1
3 (60.0%)Phase 2
2 (40.0%)The Evaluation of the Drug R3R01 for the Excretion of Protein in the Urine in Patients With Diabetic Kidney Disease.
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-04-02
- Lead Sponsor
- River 3 Renal Corp.
- Target Recruit Count
- 60
- Registration Number
- NCT06600412
- Locations
- 🇩🇰
Steno Diabetes Center Copenhagen, Copenhagen, Denmark
Study to Evaluate R3R01 in Patients With Alport Syndrome and Patients With Focal Segmental Glomerulosclerosis
Phase 2
Active, not recruiting
- Conditions
- Focal Segmental GlomerulosclerosisAlport Syndrome
- Interventions
- First Posted Date
- 2022-03-04
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- River 3 Renal Corp.
- Target Recruit Count
- 50
- Registration Number
- NCT05267262
- Locations
- 🇺🇸
Investigative Site, Dallas, Texas, United States
🇬🇧Investigative site, Nottingham, United Kingdom
News
No news found